1 / 20

Testing the H1N1 Pandemic Flu Vaccines

Testing the H1N1 Pandemic Flu Vaccines. Mexico City, Time Magazine , April 2009. Mini-Med School. Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September 8, 2010. Unfolding of the H1N1 flu pandemic. Feb 2009: First cases in Mexico

gunnar
Download Presentation

Testing the H1N1 Pandemic Flu Vaccines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Testing the H1N1 Pandemic Flu Vaccines Mexico City, TimeMagazine, April 2009 Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September 8, 2010

  2. Unfolding of the H1N1 flu pandemic • Feb 2009: First cases in Mexico • April 15: First cases detected in U.S. • April 26: DHHS declares Public Health Emergency • May 29: Cases in 49 U.S. states and 53 countries • June 11: WHO declares a Global Pandemic • Aug 4: • Global: 162,380 confirmed cases and 1,154 deaths • U.S.: 6,506 hospitalizations and 436 deaths

  3. What is Influenza? • Viral infection of respiratory tract • Spreads person-to-person by coughing and sneezing • Usually wintertime • Symptoms: Fever, runny nose, cough, sore throat, body aches • 20,000-40,000 deaths each year

  4. Triple reasssortant swine flu viruses (genes from human, swine, and birds) have been identified in swine in the US since 1998 • 12 cases in humans were identified in 2005-9 • On April 15 and 17, two cases were identified in US with a new combination of gene segments

  5. How does H1N1 flu behave differently from standard, “seasonal” flu?

  6. Ventured into warmer months Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient ILI Surveillance Network (ILINet), National Summary 2008-2009 and Previous Two Seasons, until Week Ending August 1, 2009) May 1, 2009

  7. Affected people are younger than with seasonal flu From EU July 2009

  8. Distribution of deaths from H1N1 flu in U.S. by age group

  9. H1N1 is more contagious than season flu 2009 H1N1

  10. The result is..

  11. Risk groups for H1N1 pandemic 2009 flu • People with chronic conditions in the particularly those that compromise their immunity or respiratory function, including severe or morbid obesity • Pregnant women • Young children (particularly those less than 2 years of age)

  12. Flu strains expected to circulate in community Weakened • Killed • Split • Purified Vaccines are highly effective in preventing flu Inactivated flu shot Live, nasal spray vaccine H1N1 vaccine is made the same way

  13. Studies are needed to inform policy People with some immunity respond better to flu vaccines – we need to know the best way to vaccinate a population that has little pre-existing immunity • How many doses are needed in different age groups • Can the standard strength be used or is a higher strength vaccine needed? • Can H1N1 vaccine be given at the same time as the seasonal flu vaccine? • Is it safe and effective in persons at increased risk? • Are there ways to make the vaccine work at lower doses so there’s more to go around? • Studies at the Vaccine Testing and Evaluation Units will attempt to answer these questions

  14. NIAID Vaccine Testing and Evaluation Units

  15. Study Overview • 200 subjects age 18-64 years old • 200 subjects age ≥ 65 years old • 200 subjects 6-35 months • 200 subjects 3-9 years • 200 subjects 10-17 years • Multiple Sites If safe,

  16. Dose 1 Dose 2 21 days 21 days Rationale for This Study • Explore two dose levels: 15 mcg “standard” 30 mcg “high-dose” • Explore 1 dose or 2 doses: • Explore how quickly immune responses likely to be protective are elicited

  17. Methods • Safety and Reactogenicity 7-day Diary after each dose Adverse Effects at each of 5 visits plus phone calls for 7 months Changes in Medical History and Medications • Immunogenicity Serum Antibody Week 1 Week 2 Week 3 Week 4 Week 5 Week 6

  18. Vaccine available Study results available Impact Cases Summer School Winter starts

  19. How to avoid contracting swine H1N1 flu

  20. How to avoid contracting swine H1N1 flu

More Related